🗓️Today, IFPMA is hosting a platform to explore the different types of partnerships that supported the manufacturing scale-up of vaccines & treatments during #COVID19.
Delighted to welcome companies who partnered to deliver #COVID19#vaccines & treatments to share experiences of voluntary licensing, tech transfer & other collaborations.
Discussion explores the frameworks that allowed them to take place.
Discussion now about the value in adopting diverse forms of partnership. No single approach is right for every company or counterpart. #AlwaysInnovating
Four key elements helped foster these partnerships:
•Trusted relationships
•Innovation ecosystem
•Safety track record
•Trained workforce
As we prepare for future pandemics, we need to preserve what worked well in the response to #COVID19.
Supporting a thriving innovation ecosystem and building stronger partnerships across the supply chain are crucial. #AlwaysInnovating
• • •
Missing some Tweet in this thread? You can try to
force a refresh
On 3-5 June, IFPMA joined the 3rd @g20org Health Working Group meeting in Hyderabad, India and brought the innovative pharma industry's perspectives on #G20 global health priorities.
⬇️Read this thread to find out more
On 3 June, we attended an event on the "Global Vaccine Research Collaborative,” stressing our commitment to the #100DaysMission.
We stated that the Health Emergencies Prevention, Preparedness & Response (#HEPPR) includes duplicative and fragmented proposals, which are not fit-for-purpose for the private sector.